www.hirntumorhilfe.de
Herzlich willkommen im Forum der Deutschen Hirntumorhilfe!

Thema: Aloe - wer hat Erfahrungen

Aloe - wer hat Erfahrungen
Olaf[a]
30.05.2002 13:07:40
Die Heilpflanze Aloe scheint derzeit als begleitendes Behandlungsmittel wiederentdeckt zu werden. Und das bei der Behandlung von schweren Erkrankungen wie Krebs, Aids und mehreren Dutzend weiteren Krankheiten.
Hat jemand Erfahrungen damit? Gibt es bereits Studien, die die beschriebenen Erfolge belegen? Was meinen unsere Medinziner zu solchen oder ähnlichen Nahrungsergänzungen?

PS: Ich suche immer noch nach einem Internisten/Onkologen für meinen Vater (Hirnmtetastase nach Lungenkarzinom). Nach OP und radiatio würde er an seinen überweisenden HNO-Arzt "zurückgegeben" werden. An der Uni Leipzig, wo er derzeit behandelt wird, fühlt sich keiner zuständig für die Suche nach einem eventuellen Primärtumor! Gibt es öffentliche Arztverzeichnisse?

Viele Grüße
Olaf[a]
Thorsten M
02.06.2002 15:49:35
Hallo Olaf,

bzgl. Melatonin und Aloe Vera gibt es Studien die in Italien durchgeführt wurden.
In der ersten Studie wurde nur Melatonin eingesetzt und mit den Ergebnissen der 2.Studie (Melatonin + Aloe Vera) verglichen.

Rezept für selbstgemachten Aloe Vera Saft:
1 grosses 4-5 Jahre altes Aloe Vera Barbadensis Miller Blatt, ca. 700 - 800 g
2 x 500 ml guten Honig
3 - 4 Esslöffel klarer Schnaps
Blatt waschen und Rand abschneiden. Alles in kleine Würfel scheiden und im Mixer zusammen mit dem Klaren pürieren. Sollte für ca. 6 - 8 Wochen reichen.
Bitte im Kühlschrank aufbewahren. Zu Beginn ca. 50 ml trinken. Danach ca. 10 ml morgens und abends. In der Schale ca. 300 % mal Wirstoff enthalten als im Gel !!!
Achtung: Die abfürenden Substanzen sind hier nicht ausgefiltert.


Hier die Artikel:

Oncology 1996 Jan-Feb;53(1):43-6

Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.

Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G

Division of Oncological Radiotherapy, San Gerardo Hospital, Monza, Italy.

The prognosis of brain glioblastoma is still very poor and the median survival time is generally less than 6 months. At present, no chemotherapy has appeared to influence its prognosis. On the other hand, recent advances in brain tumor biology have suggested that brain tumor growth is at least in part under a neuroendocrine control, mainly realized by opioid peptides and pineal substances. On this basis, we evaluated the influence of a concomitant administration of the pineal hormone melatonin (MLT) in patients with glioblastoma treated with radical or adjuvant radiotherapy (RT). The study included 30 patients with glioblastoma, who were randomized to receive RT alone (60 Gy) or RT plus MLT (20 mg/daily orally) until disease progression. Both the survival curve and the percent of survival at 1 year were significantly higher in patients treated with RT plus MLT than in those receiving RT alone (6/14 vs. 1/16). Moreover, RT or steroid therapy-related toxicities were lower in patients concomitantly treated with MLT. This preliminary study suggests that a radioneuroendocrine approach with RT plus the pineal hormone MLT may prolong the survival time and improve the quality of life of patients affected by glioblastoma.
Nat Immun 1998;16(1):27-33

Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.

Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F

Division of Radiation Oncology, San Gerardo Hospital, Monza, Milan, Italy.

The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology. Either cytokines such as IL-2, or neurohormones, such as the pineal indole melatonin (MLT), may activate anticancer immunity. In addition, immunomodulating substances have also been isolated from plants, particularly from Aloe vera. Preliminary clinical studies had already shown that MLT may induce some benefits in untreatable metastatic solid tumor patients, whereas, for the time being, no clinical trial has been performed with aloe products. We have carried out a clinical study to evaluate whether the concomitant administration of aloe may enhance the therapeutic results of MLT in patients with advanced solid tumors for whom no effective standard anticancer therapies are available. The study included 50 patients suffering from lung cancer, gastrointestinal tract tumors, breast cancer or brain glioblastoma, who were treated with MLT alone (20 mg/day orally in the dark period) or MLT plus A. vera tincture (1 ml twice/day). A partial response (PR) was achieved in 2/24 patients treated with MLT plus aloe and in none of the patients treated with MLT alone. Stable disease (SD) was achieved in 12/24 and in 7/26 patients treated with MLT plus aloe or MLT alone, respectively. Therefore, the percentage of nonprogressing patients (PR + SD) was significantly higher in the group treated with MLT plus aloe than in the MLT gorup (14/24 vs. 7/26, p < 0.05). The percent 1-year survival was significantly higher in patients treated with MLT plus aloe (9/24 vs. 4/26, p < 0.05). Both treatments were well tolerated. This preliminary study would suggest that natural cancer therapy with MLT plus A. vera extracts may produce some therapeutic benefits, at least in terms of stabilization of disease and survival, in patients with advanced solid tumors, for whom no other standard effective therapy is available.

Alles Gute
Thorsten M
Thorsten M
NACH OBEN